Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 11/20 | 0.49 |
| ▸ | MMP1 | P03956 | 10/20 | 0.49 |
| ▸ | MMP2 | P08253 | 10/20 | 0.49 |
| ▸ | REN | P00797 | 2/20 | 0.46 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.43 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272048 | 1.00 | CTSS (0.53) | CTSSCTSLCTSKMMP3MMP1 | |
| SCHEMBL12742961 | 0.95 | CTSS (0.55) | CTSSCTSLCTSKMMP3MMP1 | |
| SCHEMBL313931 | 0.92 | CTSS (0.48) | CTSSCTSLCTSKMMP3MMP1 | |
| SCHEMBL272047 | 0.92 | CTSS (0.48) | CTSSCTSLCTSKMMP3MMP1 | |
| SCHEMBL12742962 | 0.91 | REN (0.54) | CTSSCTSLCTSKMMP3MMP1 | |
| SCHEMBL12742964 | 0.81 | MMP1 (0.48) | CTSSCTSLCTSKMMP3MMP1 | |
| SCHEMBL12823958 | 0.81 | CTSL (0.57) | CTSSCTSLCTSKMMP3MMP1 | |
| SCHEMBL272046 | 0.81 | CTSL (0.57) | CTSSCTSLCTSKMMP3MMP1 | |
| SCHEMBL12742970 | 0.81 | CTSS (0.59) | CTSSCTSLCTSKMMP3MMP1 | |
| SCHEMBL12742973 | 0.79 | MMP3 (0.43) | CTSSCTSLCTSKMMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133864-B2 | PAR-2 agonist | KOWA COMPANY, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090215703-A1 | PAR-2 Agonist | KOWA COMPANY, LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
| US-20090215703-A1 | PAR-2 Agonist | KOWA COMPANY, LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215703-A1 | PAR-2 Agonist | FPR2, F2RL1, FPR3 | CTSS 1558/4885CTSL 1479/4885CTSK 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.